Memorial Sloan Kettering's Genomic Expertise Gets AI Wings as OpenEvidence Targets 1.12 Million Clinicians

OpenEvidence is bringing Memorial Sloan Kettering Cancer Center's precision oncology expertise to more than a million U.S. clinicians through a new partnership that integrates MSK's OncoKB knowledge base into its AI clinical decision support platform. The collaboration, announced following OpenEvidence's $250 million funding round in early September 2026, represents a strategic push to embed subspecialty medical intelligence directly into physician workflows at the point of care.

The partnership gives OpenEvidence's 1.12 million NPI-verified U.S. clinicians—including physicians, nurses, nurse practitioners, and physician assistants—access to MSK's evidence-based genomic interpretation tools. OncoKB provides clinically actionable assertions on genetic alterations as biomarkers, complete with cancer type-specific annotations detailing oncogenic effects, levels of evidence, and associated therapies. The integration extends into Epic EHR systems, where MSK itself plans to deploy OpenEvidence within its own clinical workflows.

Democratizing Precision Oncology Beyond Academic Centers

The collaboration addresses a persistent gap in precision medicine: community oncologists and non-specialist physicians often lack the genomic interpretation expertise concentrated at academic cancer centers. By embedding OncoKB directly into the platforms where clinicians already work, OpenEvidence aims to reduce disparities between top-tier institutions and community practices in rural or under-resourced areas.

OpenEvidence processed over 40 million NPI-verified queries from U.S. clinicians in August 2026 alone, according to the company. The MSK partnership builds on existing oncology-focused collaborations, including a licensing agreement with the National Comprehensive Cancer Network (NCCN) for evidence-based guidelines and integration of ASCO Guidelines. OpenEvidence has indicated plans to develop therapies using combined MSK and NCCN data, though details remain limited.

The "Medical Superintelligence" Strategy

OpenEvidence is pursuing what it calls a "medical superintelligence" approach—building specialized AI sub-agents for clinical domains rather than a single generalist model. The oncology focus represents the first major deployment of this strategy, with genetics, cardiology, and neurology agents planned for future release.

The company operates multiple AI models tailored to different clinical scenarios: Osler serves as the fastest option at approximately five seconds and functions as the default for point-of-care queries, while Sackett conducts deeper searches for evidence-weighted questions. A third model, Snow, was mentioned but not fully described in available materials.

OpenEvidence recently unveiled Darwin, a new AI model that achieved a perfect score on the MedQA benchmark. The model also posted scores of 72.8% on MedXpertQA, 82.7% on HealthBench Professional, and 87.2% on NOHARM. Darwin remains in research preview, available only by application to institutional partners such as the National Organization for Rare Disorders, research collaborators, and accredited AI researchers at academic institutions.

Market Positioning and Competitive Implications

The partnership comes as OpenEvidence commands a $15 billion valuation following its funding round led by Byers Capital and Andreessen Horowitz. The company's subspecialty strategy contrasts with competitors pursuing generalist medical AI approaches, potentially establishing a new competitive axis in the clinical decision support market.

According to Dr. Anaeze Offodile, MSK's chief strategy officer, and OpenEvidence founder Daniel Nadler, Ph.D., the collaboration reflects confidence in domain-specific, evidence-based AI over general-purpose medical tools. Whether this model proves more effective than generalist approaches will likely depend on adoption rates among community practices and the quality of workflow integration.

Sources

1. OpenEvidence, Memorial Sloan Kettering Cancer Center partner to bring precision oncology AI to more doctors — Fierce Healthcare